Korea/Asia, Events, IPOs, Douglas Research Advisory

Douglas Kim

Korea/Asia, Events, IPOs

Douglas Research Advisory

Equity Capital Markets

<ul>
<li>Aimedbio is getting ready to complete its IPO in KOSDAQ in November 2025. The IPO price range is from 9,000 won to 11,000 won per share.</li>
<li>According to the bankers' IPO price range, the expected market cap after the IPO is from 599 billion won to 732 billion won.</li>
<li>Aimedbio has advanced multiple antibody-drug conjugates (ADC) candidates into preclinical and early clinical stages.</li>
</ul>


Aimedbio is getting ready to complete its IPO in KOSDAQ in November 2025. The IPO price range is from 9,000 won to 11,000 won per share.
According to the bankers' IPO price range, the expected market cap after the IPO is from 599 billion won to 732 billion won.
Aimedbio has advanced multiple antibody-drug conjugates (ADC) candidates into preclinical and early clinical stages.


South Korea

Aimed Bio Inc. provides medical technology development seervices. The Company develops cancer cell-targeting antibody technologies and other products. Aimed Bio conducts businesses in South Korea.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Aimed Bio (0009K0 KS)

Aimedbio IPO Preview

Aimedbio is getting ready to complete its IPO in KOSDAQ in November 2025. Aimedbio has advanced multiple antibody-drug conjugates (ADC) candidates...

Douglas Kim

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)